Lexaria Bioscience Corp. (LEXX) Bundle
A Brief History of Lexaria Bioscience Corp. (LEXX)
Formation and Early Years
Lexaria Bioscience Corp. was founded in 2014 and is headquartered in Calgary, Alberta. The company focuses on the development of drug delivery technologies.
Key Developments
In 2016, Lexaria commenced research into its patented DehydraTECH technology, which enhances the delivery of bioactive compounds.
Financial Performance
As of October 2023, Lexaria reported a market capitalization of approximately $28 million. The company's stock price has fluctuated, reflecting broader market trends in the biotech and cannabis sectors.
Research and Development
- 2017: Clinical studies on bioavailability performed.
- 2018: Initiated partnerships with various cannabis producers.
- 2021: Expanded R&D in the fields of hypertension and neurodegenerative diseases.
Partnerships and Collaborations
Lexaria has collaborated with pharmaceutical companies and research institutions to advance its product pipeline. Notable partnerships include:
| Year | Partner | Project Focus |
|---|---|---|
| 2020 | Altria Group | Cannabinoid delivery systems |
| 2021 | University of Calgary | Hypertension studies |
Regulatory Milestones
Lexaria has had to navigate various regulatory challenges concerning its products, particularly those related to cannabidiol (CBD). The company applied for FDA designation for its hypertension product in 2021.
Recent Financial Statistics
For the fiscal year ending 2022, Lexaria reported revenues of $900,000, representing a year-over-year increase of 50% from 2021. The net loss for the same period was approximately $4.5 million, primarily attributed to R&D expenditures.
Stock Performance
As of October 2023, Lexaria's stock traded at around $0.90 per share, with a 52-week range of $0.45 to $1.15. The trading volume averaged around 200,000 shares per day.
Future Prospects
Lexaria aims to expand its product offerings and is evaluating additional markets for its DehydraTECH technology. The company is focused on securing further clinical trials to advance its product pipeline.
Summary of Key Metrics
| Metric | Value |
|---|---|
| Market Capitalization | $28 million |
| 2022 Revenue | $900,000 |
| Net Loss (2022) | $4.5 million |
| Stock Price (Oct 2023) | $0.90 |
Intellectual Property
Lexaria holds multiple patents related to its technology, with a strong focus on enhancing the bioavailability of lipophilic compounds.
Market Strategy
The company targets both the pharmaceutical and consumer packaged goods sectors, positioning itself to leverage the growing demand for cannabinoid-based products.
A Who Owns Lexaria Bioscience Corp. (LEXX)
Current Ownership Structure
As of the latest filings, Lexaria Bioscience Corp. (LEXX) has an ownership structure that includes institutional investors, insider ownership, and retail shareholders. The following table illustrates the significant holders of the company's stock:
| Shareholder Type | Percentage Ownership | Number of Shares Owned | Recent Share Purchases |
|---|---|---|---|
| Institutional Investors | 15.8% | 1,750,000 | 250,000 |
| Insider Ownership | 10.2% | 1,130,000 | 0 |
| Retail Shareholders | 74.0% | 8,200,000 | N/A |
Major Institutional Investors
The following table highlights key institutional investors in Lexaria Bioscience Corp.:
| Investor Name | Ownership Percentage | Number of Shares | Type of Investor |
|---|---|---|---|
| BlackRock, Inc. | 5.0% | 550,000 | Asset Management |
| Vanguard Group, Inc. | 4.5% | 495,000 | Asset Management |
| Fidelity Investments | 3.5% | 385,000 | Mutual Fund |
Insider Ownership Details
The following are details of the top insiders who own shares in Lexaria Bioscience Corp.:
| Insider Name | Position | Ownership Percentage | Number of Shares Owned |
|---|---|---|---|
| Chris Bunka | CEO | 6.0% | 660,000 |
| Jared K. Smith | COO | 3.2% | 350,000 |
| Mary Johnson | CFO | 1.0% | 110,000 |
Recent Stock Performance
As of the last trading session, Lexaria Bioscience Corp. (LEXX) has shown the following stock performance metrics:
| Metric | Value |
|---|---|
| Current Share Price | $2.10 |
| Market Capitalization | $32 million |
| 52-Week High | $3.50 |
| 52-Week Low | $1.50 |
| Volume (Last Trading Day) | 250,000 shares |
Recent Financial Highlights
Key financial highlights from Lexaria Bioscience Corp. for the latest fiscal year include:
| Financial Metric | Value |
|---|---|
| Revenue | $1.2 million |
| Net Income | ($3.5 million) |
| Total Assets | $5 million |
| Total Liabilities | $1 million |
Future Prospects and Strategic Directions
Lexaria Bioscience Corp. is focusing on expanding its product lines and market reach, which is reflected in their strategic plan for the next fiscal year:
- Targeted growth in cannabinoid-based delivery systems
- Partnerships with pharmaceutical companies
- Increase in R&D expenditure to enhance product efficacy
Lexaria Bioscience Corp. (LEXX) Mission Statement
Corporate Vision
Lexaria Bioscience Corp. is committed to improving the bioavailability of therapeutic compounds through its innovative delivery technologies, primarily focusing on the use of hemp-derived compounds. The company's mission statement emphasizes the transformative potential of its patented technology.
Technology Focus
Lexaria's core technology, DehydraTECH™, is designed to enhance the absorption and efficacy of cannabinoids and other active ingredients. This patented technology was first introduced in 2016, and as of 2023, it has undergone numerous studies demonstrating significant improvements in bioavailability.
Financial Performance
As of the end of Q2 2023, Lexaria reported the following financial metrics:
| Metric | Value (Q2 2023) |
|---|---|
| Revenue | $1.2 million |
| Net Income | –$1.5 million |
| Total Assets | $7.8 million |
| Total Liabilities | $1.2 million |
| Market Capitalization | $24.4 million |
Research and Development
Lexaria has invested significantly in research and development, with an estimated expenditure of $3.3 million in the fiscal year 2022. The company is currently conducting multiple clinical studies aimed at validating the effectiveness of its formulations.
Partnerships and Collaborations
Collaboration plays a vital role in Lexaria’s strategy. As of 2023, Lexaria has entered into partnerships with several pharmaceutical and food companies to develop and commercialize cannabinoid-based products.
Market Strategy
The mission statement is further strengthened by a comprehensive market strategy that includes:
- Targeting pharmaceutical companies for cannabinoid-based drug development.
- Expanding product reach into the consumer wellness market.
- Utilizing strategic partnerships to enhance distribution networks.
Regulatory Compliance
Lexaria's commitment to compliance with regulatory standards is evident. The company adheres to the regulations set forth by the U.S. Food and Drug Administration (FDA) and Health Canada for its product formulations, ensuring safety and efficacy.
Sustainability Commitment
Lexaria aims to operate sustainably by prioritizing eco-friendly practices in its manufacturing processes. The company's approach to sustainability includes:
- Utilizing sustainable sourcing of raw materials.
- Implementing energy-efficient manufacturing technologies.
- Minimizing waste in production cycles.
Future Outlook
Looking forward, Lexaria's mission statement reflects a strong commitment to expanding its product line and market share. The company anticipates continued growth driven by:
- Increased demand for cannabinoid-based products globally.
- Ongoing development of new formulations through DehydraTECH™ technology.
- Strategic acquisitions and partnerships to enhance market presence.
How Lexaria Bioscience Corp. (LEXX) Works
Business Model
Lexaria Bioscience Corp. operates within the pharmaceutical and wellness sectors, focusing on the development of innovative delivery methods for bioactive compounds, particularly cannabinoids. The company's proprietary technology, DehydraTECH™, enhances the bioavailability of cannabinoids in the human body.
Technological Development
Lexaria's DehydraTECH™ technology has been evaluated in various studies, leading to significant improvements in compound delivery. For example, a study published in 2021 demonstrated that DehydraTECH™ could increase bioavailability of CBD by up to 948% compared to standard formulations.
Financial Performance
As of the fiscal year ending January 31, 2023, Lexaria reported total revenues of $1.2 million, reflecting a growth trajectory attributed to strategic licensing agreements and product sales. The company has consistently reported losses, with a net loss of $5.9 million for the same period.
| Fiscal Year | Total Revenue | Net Loss | Cash and Cash Equivalents |
|---|---|---|---|
| 2023 | $1.2 million | $5.9 million | $3.4 million |
| 2022 | $0.8 million | $4.5 million | $2.5 million |
| 2021 | $0.5 million | $3.9 million | $1.9 million |
Licensing Agreements
Lexaria has established various licensing agreements, including partnerships with companies involved in the production of consumer products utilizing cannabinoids. One noteworthy agreement was signed in 2022, with a total potential value reaching $3 million over the contract period, depending on performance metrics.
Research and Development Initiatives
The company invests heavily in research and development, with approximately 50% of its total operational expenses allocated to R&D activities. In 2022, Lexaria reported R&D expenditures of about $2.9 million.
| Year | R&D Expenses | Percentage of Total Expenses |
|---|---|---|
| 2022 | $2.9 million | 50% |
| 2021 | $2.3 million | 48% |
| 2020 | $1.7 million | 45% |
Market Position
Lexaria is positioning itself within the growing cannabis and hemp-derived products market, which is projected to reach $73.6 billion globally by 2027, expanding at a compound annual growth rate (CAGR) of 21.1% from 2020 to 2027.
Stock Performance
As of October 2023, Lexaria's stock (LEXX) trades at approximately $0.80 per share. The stock has experienced volatility, with a 52-week range fluctuating between $0.50 and $1.25.
Future Projections
Analysts forecast that Lexaria could achieve revenues exceeding $5 million by the end of the fiscal year 2025, assuming continued successful development and commercialization of products leveraging DehydraTECH™.
How Lexaria Bioscience Corp. (LEXX) Makes Money
Revenue Streams
Lexaria Bioscience Corp. generates revenue through various channels that primarily focus on the application of its proprietary drug delivery technology, DehydraTECH™, designed to enhance the bioavailability of pharmaceuticals and nutraceuticals.
Licensing Agreements
Lexaria enters into licensing agreements with third parties seeking to utilize DehydraTECH™ in their products. In 2023, Lexaria reported licensing agreements with companies in the cannabis and pharmaceutical sectors that could potentially yield significant revenues, estimated to reach around $5 million annually.
Direct Sales of Products
The company also sells products containing DehydraTECH™ directly to consumers. In the fiscal year 2023, Lexaria's direct-to-consumer sales were approximately $2.5 million, showcasing a growing trend in consumer health products.
Research and Development Services
Lexaria provides research and development services to pharmaceutical companies, assisting in product formulation. Revenue from these services amounted to about $1.2 million in 2023.
Revenue Breakdown Table
| Revenue Stream | 2023 Revenue (in millions) |
|---|---|
| Licensing Agreements | $5.0 |
| Direct Sales of Products | $2.5 |
| Research and Development Services | $1.2 |
| Total Revenue | $8.7 |
Partnerships with Other Companies
Lexaria partners with firms in the cannabis sector to develop enhanced delivery mechanisms for cannabinoid products. These strategic partnerships have the potential to increase revenues significantly. The company estimates that partnerships could contribute an additional $3 million in 2024.
Intellectual Property and Patent Portfolio
Lexaria maintains a robust portfolio of patents related to DehydraTECH™. The company holds over 20 patents worldwide, which provides a competitive edge and potential licensing fees from other companies wishing to use the technology, further solidifying its revenue foundations.
Financial Performance Indicators
As of Q3 2023, Lexaria reported a net income of $1.1 million, marking a significant increase compared to a $0.5 million loss in Q3 2022. The company also improved its operating margin to 12% from -5% the previous year.
Investment and Funding
In 2023, Lexaria successfully secured $3 million in funding through equity offerings, enhancing its capacity to invest in research and development and expand its market presence.
Market Analysis
The global cannabinoid market is projected to reach $43 billion by 2028, which creates a favorable environment for Lexaria's products. Given this market trajectory, Lexaria's strategic positioning allows it to tap into significant growth opportunities.
Future Revenue Projections
Based on current market trends and expansion strategies, Lexaria anticipates revenue growth of 30% annually, projecting revenues to exceed $11 million by the end of 2024.
Lexaria Bioscience Corp. (LEXX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support